Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

This week, the FDA rejected Merck's MRK and AbbVie’s ABBV regulatory filings seeking approvals for pipeline candidates, patritumab deruxtecan and ABBV-951, respectively. AstraZeneca AZN announced the failure of an early-stage lung https://www.nasdaq.com/articles/pharma-stock-roundup-fdas-crl-mrk-abbv-phase-iii-study-failures-nvo-azn